Do you want to read an article? Please log in or register.
EGFR-mutant lung adenocarcinoma transformed into small cell Lung cancer: A case report and literatures review
Further Publications
Related content
Lung Cancer
Definition of resectable stage III non-small cell lung cancer: A systematic review from EORTC lung cancer group
Lung Cancer
Xenophontos E, Giaj Levra N, Durieux V, van Geffen WH, Grisay G, De la Pinta Alonso C, Arasanz H, Prisciandaro E, Ferrara R, Derks J, Von der Thusen J, Dickhoff C, Brandão M, Faivre-Finn C, Edwards J, Ruysscher D, Remon J, Dingemans AC, Berghmans T
doi: 10.1016/j.lungcan.2025.108671
RECOMMENDED
Lung Cancer
Decoding KRAS mutation in non-small cell lung cancer patients receiving immunotherapy: A retrospective institutional comparison and literature review
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Urtecho SB, Provenzano L, Spagnoletti A, Bottiglieri A, Pircher C, Massa G, Sposetti C, Proto C, Brambilla M, Occhipinti M, Mazzeo L, Beninato T, Leporati R, Giani C, Cavalli C, Serino R, Prina MM, Bassetti A, Nasca V, di Mauro RM, Abate A, Manglaviti S, Dumitrascu AD, Liberti GD, Cassano TS, Ganzinelli M, Wu S, Garassino MC, de Braud FGM, Russo GL, Prelaj A
doi: 10.1016/j.lungcan.2024.108051
Further Publications
Successful stent removal after chemoradiotherapy followed by durvalumab for locally advanced non-small cell lung cancer with airway stenosis: A report of three cases
Respir Med Case Rep
Takigawa Y, Sato K, Minami D, Kudo K, Matsumoto S, Fujiwara M, Ichikawa T, Inoue T, Matsuoka S, Watanabe H, Sato A, Shoda H, Ishikawa N, Fujiwara K, Shibayama T
doi: 10.1016/j.rmcr.2025.102217
Lung Cancer
Real-world data of dacomitinib as first-line treatment for patients with EGFR-mutant non-small-cell lung cancer
Sci Rep
Shin JE, Jung HA, Park S, Sun JM, Lee SH, Ahn JS, Ahn MJ, Shim BY
doi: 10.1038/s41598-024-81704-4
RECOMMENDED
Lung Cancer
Neoadjuvant Aumolertinib for unresectable stage III EGFR-mutant non-small cell lung cancer: a single-arm phase II trial
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Nat Commun
Bian D, Ji S, Liu Y, Huang Z, Jiang L, Liu M, Bao X, Yang J, Zhou Y, Hu J, Sun L, Zheng Y, Huang J, Liu J, Zhu X, Zhang J, Zhang L, Liu X, He W, Xie D, Zhu Y, Wu C, Zhao D, Duan L, Jiang G, Zhang P
doi: 10.1038/s41467-025-58435-9
Lung Cancer
Clinical Outcomes of Compound EGFR Mutations in Non-Small Cell Lung Cancer: A National, Retrospective, Multicenter Study
Clin Lung Cancer
Atlagh L, Toublanc AC, Roch B, Marinello A, Ruuth-Praz J, Cousin S, Chouaid C, Basset C, Evrard S, Duruisseaux M, Girard N, Durand K, Mazières J, Brindel A
doi: 10.1016/j.cllc.2025.06.005
Lung Cancer
Real-World Outcomes in BRAF-Mutant Non-small Cell Lung Cancer: A Multicenter Analysis From the Turkish Oncology Group
Clin Lung Cancer
Telli TA, Tatlı AM, Alan Ö, Keskin GY, Karadurmuş N, Karakaya S, Kaplan MA, Açıkgöz Ö, Bilici A, Mocan EE, Demirkazık A, Kahraman S, Şendur MA, Doğan M, Selam MT, Er Ö, Ünsal O, Yazıcı O, Özcan E, Kargı A, Gürbüz M, Selçukbiricik F, Şakalar T, Gürsoy P, Bilgin B, Selvi O, Karadağ İ, Eren OÖ, Bayram E, Sümbül AT, Keskin S, Öztürk A, Topçu S, Özen M, Kılıçkap S, Yumuk PF
doi: 10.1016/j.cllc.2025.07.015
Lung Cancer
Osimertinib as First-Line Treatment for Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in a Real-World Setting: Updated Overall Survival Data (OSI-FACT-OS)
Clin Lung Cancer
Sakata Y, Saito G, Sakata S, Yamaguchi T, Tamiya M, Suzuki H, Shibaki R, Okada A, Yokoyama T, Matsumoto H, Otsuki T, Sato Y, Uchida J, Tsukita Y, Inaba M, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Morinaga J, Sakagami T
doi: 10.1016/j.cllc.2025.05.015
Lung Cancer
Segmentectomy vs. Lobectomy in stage IA non-small cell lung cancer: A systematic review and meta-analysis of perioperative and survival outcomes
Lung Cancer
Bertolaccini L, Tralongo AC, Del Re M, Facchinetti F, Ferrara R, Franchina T, Graziano P, Malapelle U, Menis J, Passaro A, Pilotto S, Ramella S, Rossi G, Trisolini R, Cinquini M, Passiglia F, Novello S
doi: 10.1016/j.lungcan.2024.107990